Homepage Top Section2

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour

HFB30132A is said to have been discovered, engineered, and developed in less than six months by the US-based HiFiBiO Therapeutics. The company said that its partnership with ABL

As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets

The company has reported positive pre-clinical results and confirmed the efficacy of the vaccine on the live SARS CoV-2 virus. ACvac1 is a prophylactic COVID-19 vaccine designed to

AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved

Under the deal, Mylan will acquire Aspen’s portfolio that includes injectable anticoagulants marketed in Europe under the brand names and variations of the brand names such as Arixtra,

The German company said that 41% of PAH patients transitioning to Adempas therapy after inadequate response to  phosphodiesterase-5 inhibitors (PDE5 inhibitors) achieved the composite primary endpoint, which is

Alkahest is a clinical stage company that is focussed on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma